- Home
- ACAD vs EEFT Comparison
ACAD vs EEFT Comparison
Compare ACAD & EEFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- EEFT
- Stock Information
- Founded
- ACAD 1993
- EEFT 1994
- Country
- ACAD United States
- EEFT United States
- Employees
- ACAD N/A
- EEFT N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- EEFT EDP Services
- Sector
- ACAD Health Care
- EEFT Technology
- Exchange
- ACAD Nasdaq
- EEFT Nasdaq
- Market Cap
- ACAD 4.0B
- EEFT 3.9B
- IPO Year
- ACAD 2004
- EEFT 1997
- Fundamental
- Price
- ACAD $25.74
- EEFT $98.32
- Analyst Decision
- ACAD Buy
- EEFT Buy
- Analyst Count
- ACAD 20
- EEFT 6
- Target Price
- ACAD $28.63
- EEFT $123.83
- AVG Volume (30 Days)
- ACAD 2.0M
- EEFT 844.9K
- Earning Date
- ACAD 08-06-2025
- EEFT 07-30-2025
- Dividend Yield
- ACAD N/A
- EEFT N/A
- EPS Growth
- ACAD 615.00
- EEFT 26.28
- EPS
- ACAD 1.33
- EEFT 7.31
- Revenue
- ACAD $1,018,885,000.00
- EEFT $4,136,399,999.00
- Revenue This Year
- ACAD $13.28
- EEFT $10.58
- Revenue Next Year
- ACAD $10.88
- EEFT $8.09
- P/E Ratio
- ACAD $18.70
- EEFT $13.45
- Revenue Growth
- ACAD 14.41
- EEFT 8.71
- 52 Week Low
- ACAD $13.40
- EEFT $85.24
- 52 Week High
- ACAD $25.88
- EEFT $114.25
- Technical
- Relative Strength Index (RSI)
- ACAD 66.52
- EEFT 52.51
- Support Level
- ACAD $24.47
- EEFT $93.23
- Resistance Level
- ACAD $25.88
- EEFT $97.39
- Average True Range (ATR)
- ACAD 0.71
- EEFT 2.68
- MACD
- ACAD 0.00
- EEFT 0.54
- Stochastic Oscillator
- ACAD 94.62
- EEFT 97.65
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About EEFT Euronet Worldwide Inc.
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.